Citi lowered the firm’s price target on Bristol Myers (BMY) to $45 from $48 and keeps a Neutral rating on the shares after the company announced the discontinuation of the Librexia acute coronary syndrome trial. Citi sees higher risk to the broader program following the news.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol-Myers Squibb Faces Setbacks with Milvexian Trials, Justifying Sell Rating
- Bristol Myers Squibb put volume heavy and directionally bearish
- Bristol Myers falls 4% to $46.41 after stopping Phase 3 Librexia ACS trial
- Bristol Myers to stop Phase 3 Librexia ACS trial of milvexian
- Nike upgraded, Dollar Tree downgraded: Wall Street’s top analyst calls